Skip to main content
Journal cover image

Peginterferon Lambda-1a (Lambda) Compared to Peginterferon Alfa-2a (Alfa) in Treatment-Naive Patients With HCV Genotypes (GT) 1 or 4: SVR24 Results From EMERGE Phase 2b

Publication ,  Conference
Muir, AJ; Hillson, JL; Gray, TE; Xu, D; Ishak, L; Freeman, JA; Fontana, D; Horga, A; Lopez-Talavera, JC
Published in: HEPATOLOGY
October 1, 2012

Duke Scholars

Published In

HEPATOLOGY

ISSN

0270-9139

Publication Date

October 1, 2012

Volume

56

Start / End Page

299A / 299A

Location

Boston, MA

Publisher

WILEY-BLACKWELL

Conference Name

63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD)

Related Subject Headings

  • Gastroenterology & Hepatology
  • 3204 Immunology
  • 3202 Clinical sciences
  • 1107 Immunology
  • 1103 Clinical Sciences
  • 1101 Medical Biochemistry and Metabolomics
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Muir, A. J., Hillson, J. L., Gray, T. E., Xu, D., Ishak, L., Freeman, J. A., … Lopez-Talavera, J. C. (2012). Peginterferon Lambda-1a (Lambda) Compared to Peginterferon Alfa-2a (Alfa) in Treatment-Naive Patients With HCV Genotypes (GT) 1 or 4: SVR24 Results From EMERGE Phase 2b. In HEPATOLOGY (Vol. 56, pp. 299A-299A). Boston, MA: WILEY-BLACKWELL.
Muir, Andrew J., Jan L. Hillson, Todd E. Gray, Dong Xu, Laura Ishak, Jeremy A. Freeman, David Fontana, Arantxa Horga, and Juan Carlos Lopez-Talavera. “Peginterferon Lambda-1a (Lambda) Compared to Peginterferon Alfa-2a (Alfa) in Treatment-Naive Patients With HCV Genotypes (GT) 1 or 4: SVR24 Results From EMERGE Phase 2b.” In HEPATOLOGY, 56:299A-299A. WILEY-BLACKWELL, 2012.
Muir AJ, Hillson JL, Gray TE, Xu D, Ishak L, Freeman JA, et al. Peginterferon Lambda-1a (Lambda) Compared to Peginterferon Alfa-2a (Alfa) in Treatment-Naive Patients With HCV Genotypes (GT) 1 or 4: SVR24 Results From EMERGE Phase 2b. In: HEPATOLOGY. WILEY-BLACKWELL; 2012. p. 299A-299A.
Muir AJ, Hillson JL, Gray TE, Xu D, Ishak L, Freeman JA, Fontana D, Horga A, Lopez-Talavera JC. Peginterferon Lambda-1a (Lambda) Compared to Peginterferon Alfa-2a (Alfa) in Treatment-Naive Patients With HCV Genotypes (GT) 1 or 4: SVR24 Results From EMERGE Phase 2b. HEPATOLOGY. WILEY-BLACKWELL; 2012. p. 299A-299A.
Journal cover image

Published In

HEPATOLOGY

ISSN

0270-9139

Publication Date

October 1, 2012

Volume

56

Start / End Page

299A / 299A

Location

Boston, MA

Publisher

WILEY-BLACKWELL

Conference Name

63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD)

Related Subject Headings

  • Gastroenterology & Hepatology
  • 3204 Immunology
  • 3202 Clinical sciences
  • 1107 Immunology
  • 1103 Clinical Sciences
  • 1101 Medical Biochemistry and Metabolomics